Expertise in
12
conditions

Dr. Sanjay P. Ahuja

Hematology | Oncology
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 

Overview

Sanjay Ahuja is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio.

Dr. Ahuja is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, Venous Thromboembolism (VTE), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 74 peer reviewed articles and participating in 12 clinical trials. Dr. Ahuja is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatrics in KY

Languages Spoken

English
Hindi
Marathi
Sindhi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
View 6 Less Insurance Carriers -

Locations

University Hospitals
11100 Euclid Ave, Cleveland, OH 44106
Other Locations
Indiana Hemophilia and Thrombosis Center Inc
8326 Naab Rd, Indianapolis, IN 46260

Additional Areas of Focus

Dr. Ahuja has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors
Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors
Enrollment Status: Recruiting
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drug: Coagulation factor VIIa [recombinant]-jncw
Study Phase: Phase 4
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
Enrollment Status: Completed
Publish Date: May 15, 2026
Intervention Type: Biological
Study Drugs: Von Willebrand Factor, Factor VIII
Study Phase: Phase 3
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children
Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children
Enrollment Status: Completed
Publish Date: June 18, 2025
Intervention Type: Other
Study Phase: Phase 3
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
Enrollment Status: Completed
Publish Date: February 01, 2023
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy
Enrollment Status: Terminated
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drug: TRM-201
Study Phase: Phase 3
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
Natural History Study of Factor IX Treatment and Complications
Natural History Study of Factor IX Treatment and Complications
Enrollment Status: Unknown
Publish Date: May 25, 2021
Intervention Type: Other
View 9 Less Clinical Trials

74 Total Publications

The use of direct oral anticoagulants in children with congenital and acquired heart disease.
The use of direct oral anticoagulants in children with congenital and acquired heart disease.
Journal: Frontiers in cardiovascular medicine
Published: June 26, 2026
Similar Doctors
Expertise in
22
conditions
Dr. Jason N. Valent
Hematology | Oncology
Expertise in
22
conditions
Dr. Jason N. Valent
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Valent is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Valent is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration. Dr. Valent is currently accepting new patients.

Expertise in
23
conditions
Dr. Brad L. Pohlman
Hematology | Oncology
Expertise in
23
conditions
Dr. Brad L. Pohlman
Hematology | Oncology
Referral may be required

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (0.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Pohlman is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Pohlman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Pohlman is currently accepting new patients.

Expertise in
28
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Expertise in
28
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (0.6 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anjali Advani is a Hematologist and an Oncologist practicing medicine in Cleveland, Ohio. Dr. Advani is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Advani is board certified in American Board Of Internal Medicine, 2003. Dr. Advani is currently accepting new patients.

Frequently Asked Questions about Dr. Sanjay P. Ahuja

How do I make an appointment with Dr. Sanjay P. Ahuja?

You can book an appointment with Dr. Sanjay P. Ahuja by calling their office at 216-844-7700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sanjay P. Ahuja a top-rated expert for Hemophilia A?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sanjay P. Ahuja is classified as an Distinguished expert for Hemophilia A, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sanjay P. Ahuja specialize in?

While Dr. Sanjay P. Ahuja is a Hematology, they have specific expertise in Hemophilia A, Blood Clots, and Hemophilia B. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sanjay P. Ahuja participate in research or clinical trials?

Yes. Dr. Sanjay P. Ahuja has published 74 articles and abstracts on conditions like Hemophilia A. You can view a list of Dr. Sanjay P. Ahuja's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sanjay P. Ahuja accept my insurance?

Dr. Sanjay P. Ahuja accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 216-844-7700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ahuja's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile